Last updated 14 months ago

Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

60 patients around the world

Available in Brazil

Immix Biopharma, Inc.

2Research sites

60Patients around the world

This study is for people with

Solid tumors

Requirements for the patient

From 16 Years

All Gender

Medical requirements

Sites

Fundação Faculdade de Medicina - Instituto do Cancer do Estado de São Paulo

Recruiting

Av. Dr. Arnaldo, 455 - Cerqueira César, Pacaembu - SP, 01246-903

Centro de Estudos e Pesquisas de Hematologia e Oncologia - CEPHO

Recruiting

Av. Príncipe de Gales, 821 - Vila Principe de Gales, Santo André - SP, 09060-650

StudyIMMINENT-01

SponsorImmix Biopharma, Inc.

Conditions

Solid tumors

Requirements

From 16 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT05840835